UNSPSC 51384610: Edaravone or norphenazone

This classification denotes a neuroprotective agent with the molecular structure C10H10N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, S798V6YJRP chemically known as 3h-pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl- but generally known as edaravone, which bears US NIH Compound Identifier 4021. European Medicines Agency schedules Edaravone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06453MIG.

The term EDARAVONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, no. 3, 1996, list 36). Edaravone or norphenazone bears US NLM identifiers UMLS ID C0070694 and NCI Concept Code C74323. SMILES: O=C1N(N=C(C1)C)C1CCCCC1.

UNSPSC 51384610 Edaravone or norphenazone is a Commodity code that in practice encompasses a broader set of pharmaceutical products and related procurement activity than its narrow title suggests. Recent state and local opportunities tagged to this code show demand for naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs supporting community health, pharmacy benefit management, and emergency response initiatives. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances administering procurement on behalf of multiple jurisdictions. The work spans product supply agreements with fixed pricing and volume commitments, wholesaler distribution arrangements, and market-intelligence gathering around alternative pharmacy benefit models.

Activity is concentrated in Florida and Minnesota, with secondary engagement from Texas and cross-state participation through cooperative purchasing vehicles. Seminole County, Florida released an IFB (solicitation IFB60459723LAS) on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (solicitation S1070000015802) with response deadline March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities including Oregon, with awarded vendors effective July 1, 2026. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 gathering market intelligence on direct-to-manufacturer prescription program capabilities to inform future formal procurement strategy. All three opportunities require compliance with federal drug-supply and manufacturing standards, comprehensive insurance coverage, and electronic ordering or data-exchange systems.